^
    Back
    Association details:
    Biomarker:TP53 mutation + ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug:Ensacove (ensartinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing

    Published date:
    02/12/2021
    Excerpt:
    In a multicenter phase 2 trial, ALK-positive NSCLC patients who progressed on crizotinib were treated with ensartinib….Baseline TP53 mutations (20.2%) significantly correlated with inferior PFS (4.2 months vs 11.7 months, p < 0.0001).
    DOI:
    10.1016/j.jtho.2021.01.1615